Loading patent…
AssigneeInstitut Gustave Roussy
InventorsJean-Luc PERFETTINI, Awatef ALLOUCH, Eric DEUTSCH
Estimating the term…
Identification of effective targets alleviating the programmed cell removal (PrCR) of tumor cells by macrophages is of very high interest. The present inventors have identified that the cyclin-dependent kinase inhibitor p21 protein is a strong regulator of the macrophage-mediated PrCR. Also, they showed that the adoptive transfer of p21 overexpressing monocytes induces macrophage PrCR and transition from an anti-inflammatory to a pro-inflammatory phenotype in vivo, delays cancer progression and increases significantly the overall survival of mice engrafted with cancer cells. The present invention therefore concerns therapeutic compositions comprising monocytes that over-express the cyclin-dependent kinase inhibitor p21 protein, and their use for treating mammals suffering from cancer, especially leukemia.
1-15. (canceled)
A method for treating a mammal suffering from a lymphoid cancer or from a myeloid cancer or from a solid cancer, said method comprising administering to the mammal a pharmaceutical composition comprising a vector coding for cyclin-dependent kinase inhibitor p21 protein (p21) and a pharmaceutically acceptable excipient, wherein the vector produces genetically modified monocytes that overexpress p21 in the mammal.
Dependencies are inferred from the claim text.